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Introduction
============

For most of the last century, the leading cause of death in the United States, as measured by actual deaths, was heart disease, followed by cancer ([@R1]). Cancer overtook heart disease to become the leading cause of death in 1 state (Alaska) in 1993, 2 states in 2000, 8 states in 2005, and 23 states in 2010, although the trend slowed or stopped in recent years ([@R2],[@R3]).

The age-standardized death rate approximates the population's risk of dying from a given cause and is used to compare risk of death between populations or within a population over time. Declining death rates indicate that the overall risk to the population of dying from heart disease or cancer decreased. However, age-standardized death rates do not convey the full extent of the burden of these diseases, because they effectively remove the influence of demographic changes related to population growth and changing age structure. Although the age-standardized death rate for heart disease began to decline in the late 1960s and for all cancers combined some 20 years later, the overall number of heart disease deaths declined and the number of cancer deaths increased ([@R1],[@R4]).

The number of deaths is a function of the population risk of being diagnosed and dying from that cause and the size and age structure of the population. The risk of death from heart disease and cancer generally increases with age, and over the past several decades the US population increased, particularly in the age group 65 years or older ([@R5]). These demographic changes are forecast to continue into this century as the cohort born after World War II, with increased longevity than earlier cohorts, enters the age groups most at risk of dying from heart disease and cancer.

The objective of this study was to use mortality data, current population estimates, and population projections to predict age-standardized death rates and death counts for heart disease and cancer from 1969, around the peak of heart disease death rates (risk), through 2020 and to apportion changes in deaths resulting from population risk reduction, population growth, and population aging (ie, shift in age distribution toward older ages and increased longevity).

Methods
=======

Source of data
--------------

We obtained mortality data from 1969 through 2014 from the National Vital Statistics System ([@R6]).The underlying cause of death was assigned according to the *International Classification of Disease* (ICD) in use at the time of death, converted to ICD-10 (*International Classification of Disease*, *Revision 10*), and recoded to ensure comparability over time ([@R7]). For these analyses, we defined heart disease as rheumatic heart disease (I00--I09), hypertensive heart disease (I11), hypertensive heart and kidney disease (I13), acute myocardial infarction (I21--I22), other ischemic or coronary heart disease (I20, I23--I25), atrial fibrillation (I48), other arrhythmias (I47, I49), heart failure (I50), and other heart disease (I26--I146, I51); we defined cancer as malignant neoplasms (ICD-10: C00--97).

Bridged single-race population estimates based on the 2010 US Census were available through the Surveillance, Epidemiology, and End Results (SEER) Program ([@R8]). We obtained data on population projections of the resident population by race, age, and sex from 2015 through 2020 from the US Census Bureau's Population Projections Program ([@R9]). Population estimates and projections were used as the denominators in rate calculations.

Trends in death rates, 1969--2014
---------------------------------

We performed statistical analyses using SEER Stat software, version 8.3.2 (Surveillance Research Program \[<http://seer.cancer.gov/seerstat/>\]), calculating averaged, annual age-standardized death rates per 100,000 population and standardized to the 2000 population, by sex and race (all, white, black). We estimated trends in death rates from 1969 through 2014 using joinpoint regression (Joinpoint Trend Analysis Software, version 4.2.0.1, <http://surveillance.cancer.gov/joinpoint/>), where a maximum of 5 joined straight-line segments were fit on a logarithmic scale to the trends in annual death rates. We described the resulting trends by the slope of each line segment as the annual percentage change (APC), using *t* tests (2-sided, *P* \< .05) to assess whether the APCs were significantly different from zero. We used the terms *increase* or *decrease* to describe significant trends and *stable* to describe nonsignificant trends.

Methods for projecting cancer death rates and counts are described in detail elsewhere ([@R10]). Briefly, to project age-standardized death rates and counts for 2015 through 2020, we used Nordpred software ([@R11],[@R12]), which uses an age-period--cohort regression model with data aggregated into six 5-year calendar periods (1985--1989, 1990--1994, 1995--1999, 2000--2004, 2005--2009, 2010--2014) and 15 age groups (15--19, 20--24, 25--29, 30--34, 35--39, 40--44, 45--49, 50--54, 55--59, 60--64, 65--69, 70--74, 75--79, 80--84, ≥85 y). Separate models were constructed for heart disease causes of death and for leading cancer causes of death, by sex for all races combined. We based projections for all heart disease deaths and all cancer deaths on summed estimates among the individual disease categories. We obtained predicted death counts and age-standardized death rates by applying estimated age-specific death rates to the population projections for 2015 through 2020.

Methods to apportion the relative contribution to changes in the total number of new heart disease or cancer deaths each year that can be attributed to changes in population risk (including changes in diagnosis and treatment practices) and demographic changes related to population size and age structure are described elsewhere ([@R10]). Briefly, we generated 3 sets of data for each death year from 1969 through 2020. Baseline was defined as the number of deaths from heart disease or cancer that occurred in 1969 for men and women separately. We generated one set of data for the total number of cancer deaths that would have occurred each year if the population size and age structure remained the same as it was in 1969; this set reflects the effect of changes in population risk and is similar to the age-standardized death rate. A second set of data was generated for the total number of deaths that would have occurred if the age structure had remained the same as it was in 1969; this set reflects the effect of changes in risk and population growth. A third set of data was generated for the observed number of deaths that actually occurred and thus reflects the combined impact of changes in population risk, growth, and aging. The yearly difference between each set of death counts denotes the relative contribution to the overall change in the number of deaths since 1969 attributed to population risk, growth, and aging. A decline in risk results in negative death counts, because fewer deaths are attributed to risk compared with 1969, the baseline year.

Results
=======

The percentage change in death rates for heart disease declined among men (68.4%) and women (67.6%) ([Table 1](#T1){ref-type="table"}). By race and sex, the percentage decline was 68.8% among white men, 67.6% among white women, 59.4% among black men, and 63.8% among black women. The APCs for heart disease death rates for all races combined declined from 1969 through 2014 for men and women. By race and sex, the APC was stable in white men from 2010 through 2014 and from 2011 through 2014 for black men and women. The APC continued to decrease among white women through 2014.

###### Age-Standardized Death Rates and Overall Percentage Change and the Annual Percentage Change in Age-Standardized Death Rates by Joinpoint Analyses for Cancer and Heart Disease, by Sex and Race, 1969--2014

  Variable            ASDR 1969/2014   \% Change, 1969−2014   Trend 1   Trend 2          Trend 3   Trend 4        Trend 5                                                   
  ------------------- ---------------- ---------------------- --------- ---------------- --------- -------------- --------- ---------------- ------ ---------------- ------ ----------------
  **Heart disease**                                                                                                                                                         
  All                 520.4/166.6      −68.0                  1969      --2.8 (\<.001)   1977      --1.1 (.02)    1983      --2.4 (\<.001)   2002   --4.2 (\<.001)   2009   --1.7 (.001)
  All men             668.2/211.1      --68.4                 1969      --2.3 (\<.001)   1978      --1.3 (.04)    1983      --2.7 (\<.001)   2002   --4.1 (\<.001)   2009   --1.5 (.003)
  All women           404.4/131.1      --67.6                 1969      --3.1 (\<.001)   1977      --0.6 (.21)    1983      --2.2 (\<.001)   2002   --4.4 (\<.001)   2010   --1.6 (.05)
  All white           518.8/165.3      --68.1                 1969      --2.8 (\<.001)   1977      --1.3 (.01)    1983      --2.5 (\<.001)   2002   --4.2 (\<.001)   2009   --1.6 (.004)
  White men           673.1/210.0      --68.8                 1969      --2.0 (\<.001)   1987      --4.2 (.03)    1990      --2.1 (\<.001)   1997   --3.6 (\<.001)   2010   --1.1 (.09)
  White women         398.5/129.2      --67.6                 1969      --3.0 (\<.001)   1977      --0.8 (.15)    1983      --2.3 (\<.001)   2002   --4.4 (\<.001)   2009   --2.0 (.002)
  All black           544.0/207.1      --61.9                 1969      --2.5 (\<.001)   1977      --0.3 (.27)    1986      --2.0 (\<.001)   2002   --4.2 (\<.001)   2011   --1.0 (.36)
  Black men           643.7/261.6      --59.4                 1969      --2.2 (\<.001)   1976      --0.4 (.02)    1987      --2.2 (\<.001)   2003   --4.1 (\<.001)   2011   --0.7 (.52)
  Black women         463.7/167.9      --63.8                 1969      --3.2 (\<.001)   1976      --0.3 (.15)    1986      --1.8 (\<.001)   2002   --4.6 (\<.001)   2011   --1.2 (.33)
  **Cancer**                                                                                                                                                                
  All                 198.6/161.2      --18.8                 1969      0.2 (.32)        1974      0.5 (\<.001)   1990      --0.3 (.57)      1993   --1.1 (\<.001)   2002   --1.5 (\<.001)
  All men             247.6/193.3      --21.9                 1969      0.8 (\<.001)     1980      0.3 (\<.001)   1990      --0.5 (.38)      1993   --1.5 (\<.001)   2001   --1.8 (\<.001)
  All women           163.2/137.8      --15.6                 1969      --0.3 (.03)      1975      0.6 (\<.001)   1990      --0.2 (.55)      1994   --0.8 (\<.001)   2002   --1.4 \<.001
  All white           196.2/161.7      --17.6                 1969      0.1 (.60)        1974      0.4 (\<.001)   1991      --0.9 (\<.001)   2001   --1.4 (\<.001)   ---    ---
  White men           244.5/193.3      --20.9                 1969      0.7 (\<.001)     1980      0.2 (\<.001)   1992      --1.4 (\<.001)   2002   --1.7 (\<.001)   ---    ---
  White women         161.9/138.4      --14.5                 1969      --0.3 (.076)     1975      0.6 (\<.001)   1991      --0.6 (\<.001)   2001   --1.3 (\<.001)   ---    ---
  All black           226.0/186.3      --17.6                 1969      1.2 (\<.001)     1984      0.7 (\<.001)   1991      --0.8 (.04)      1995   --1.6 (\<.001)   2001   --2.1 (\<.001)
  Black men           289.7/233.8      --19.3                 1969      1.9 (\<.001)     1982      1.0 (\<.001)   1990      --0.2 (.79)      1993   --2.0 (\<.001)   2001   --2.7 (\<.001)
  Black women         176.3/156.9      --11.0                 1969      0.1 (.82)        1975      1.0 (\<.001)   1991      --0.6 (.004)     1999   --1.6 (\<.001)   ---    ---

Abbreviations: ---, no change from trend 4; APC, annual percentage change; ASDR, age-standardized death rates, expressed per 100,000 persons; PC, percentage change.

From 1969 through 2014, the overall cancer death rates declined among men (21.9%) and women (15.6%). By race and sex, the percentage change declined by 20.9% among white men, 14.5% among white women, 19.3% among black men, and 11.0% among black women. The APCs for cancer death rates increased between 1969 and 1990--1992 in men and women of both racial groups before declining in all groups beginning in the early 1990s through 2014.

In 1969, the risk of heart disease death (measured by the ASDR) was 2.8 times higher than the risk of cancer death among white men and 2.2 times higher among black males. In 2014, the risk of heart disease death was 1.1 times higher than the risk of cancer death among black men and lower (0.9) among white women. In 2009, the cancer death rate surpassed that for heart disease among white women while actual deaths remained higher.

[Table 2](#T2){ref-type="table"} and [Figure 1](#F1){ref-type="fig"} show the contributions to the changes in the total observed (1969--2014) and predicted (2015--2020) number of heart disease and cancer deaths by sex and year attributed to changes in population risk, growth, and aging by sex from the baseline (1969) through 2020. Compared with 1969, the number of heart disease deaths in 2020 is predicted to decrease by 21.3% among men (--73.9% risk, 17.9% growth, 34.7% aging) and 13.4% among women (--73.3% risk, 17.1% growth, 42.8% aging). Cancer deaths are predicted to increase by 91.1% among men (--33.5% risk, 45.6% growth, 79.0% aging) and 101.1% among women (--23.8% risk, 48.8% growth, 76.0% aging). In 2017, more cancer deaths are predicted than heart disease deaths in men (321,107 vs 319,793). In 2015, similar numbers of cancers deaths (281,683) as heart disease deaths (281,675) are predicted for women.

###### Observed (1969--2014) and Predicted (2015--2020) Deaths From Heart Disease and Cancer, by Sex, Apportioned Into Changes Resulting From Population Risk, Population Growth, or Population Aging Relative to 1969 (Baseline)[a](#T2FN1){ref-type="table-fn"}

  Year of Death                          Male      Female                                                      
  -------------------------------------- --------- ---------- -------- --------- --------- ---------- -------- ---------
  **Heart disease**                                                                                            
  1969                                   421,729   0          0        0         317,341   0          0        0
  1975                                   399,436   −60,516    25,660   12,562    323,216   −61,349    18,193   49,030
  1980                                   405,574   −89,778    42,441   31,182    355,364   −70,163    32,410   75,776
  1985                                   398,101   −123,117   54,444   45,045    353,282   −90,515    41,505   84,951
  1990                                   360,729   −175,024   60,056   53,968    359,225   −123,027   46,308   118,603
  1995                                   362,663   −201,350   72,780   69,504    374,807   −139,128   56,541   140,053
  2000                                   344,766   −236,214   76,871   82,379    365,935   −160,387   61,432   147,549
  2005                                   322,816   −267,501   74,560   94,027    329,238   −186,281   59,671   138,507
  2010                                   307,365   −292,876   71,356   107,156   290,296   −212,098   54,998   130,055
  2013                                   321,329   −297,415   73,479   123,535   289,753   −217,777   55,393   134,796
  2014                                   325,050   −298,886   74,109   128,098   289,255   −219,159   55,731   135,342
  2015[e](#T2FN5){ref-type="table-fn"}   319,035   −303,795   72,845   128,257   281,675   −223,641   54,188   133,787
  2016[e](#T2FN5){ref-type="table-fn"}   319,315   −306,212   72,940   130,858   278,222   −226,132   53,878   133,135
  2017[e](#T2FN5){ref-type="table-fn"}   319,793   −308,629   72,967   133,727   274,913   −228,624   53,511   132,685
  2018[e](#T2FN5){ref-type="table-fn"}   324,027   −309,659   73,837   138,121   274,964   −229,917   53,823   133,717
  2020[e](#T2FN5){ref-type="table-fn"}   331,711   −311,719   75,471   146,230   274,897   −232,504   54,354   135,706
  Change from 1969 to 2020, %            −21.3     −73.9      17.9     34.7      −13.4     −73.3      17.1     42.8
  **Cancer**                                                                                                   
  1969                                   175,404   0          0        0         146,360   0          0        0
  1975                                   198,586   5,438      12,849   4,895     171,143   −2,128     10,245   16,666
  1980                                   225,943   12,260     24,002   14,276    190,554   2,939      19,570   21,685
  1985                                   246,917   14,237     34,561   22,715    214,646   7,913      28,238   32,135
  1990                                   268,292   14,723     46,283   31,882    237,047   10,734     37,450   42,504
  1995                                   281,635   4,331      59,391   42,509    256,852   8,839      49,257   52,396
  2000                                   286,072   −10,514    68,316   52,866    267,008   1,894      58,041   60,713
  2005                                   290,417   −25,278    72,560   67,731    268,886   −8,046     62,978   67,594
  2010                                   301,032   −38,505    75,803   88,331    273,706   −18,104    67,000   78,450
  2013                                   307,553   −46,564    76,036   102,676   277,319   −23,957    67,769   87,146
  2014                                   311,285   −48,486    76,568   107,799   280,401   −25,333    68,699   90,675
  2015[e](#T2FN5){ref-type="table-fn"}   315,189   −50,251    77,304   112,733   281,683   −27,350    68,825   93,848
  2016[e](#T2FN5){ref-type="table-fn"}   317,789   −52,385    77,677   117,093   283,162   −29,144    69,241   96,706
  2017[e](#T2FN5){ref-type="table-fn"}   321,107   −54,519    77,990   122,232   285,294   −30,939    69,618   100,255
  2018[e](#T2FN5){ref-type="table-fn"}   326,119   −55,911    78,728   127,898   288,432   −32,231    70,265   104,038
  2020[e](#T2FN5){ref-type="table-fn"}   335,283   −58,695    80,066   138,508   294,297   −34,814    71,466   111,285
  Change from 1969 to 2020, %            91.1      −33.5      45.6     79.0      101.1%    −23.8      48.8     76.0

Values are number unless otherwise noted.

Changes in deaths because of change in population risk of death.

Changes in deaths because of change in population growth.

Changes in deaths because of change in population aging.

Predicted values.

![Trends in observed (1969--2014) and predicted (2015--2020) heart disease and cancer deaths attributed to the average person's risk of dying from the disease (ie, population risk, accounting for such factors as changes in diagnostic and treatment practices), population growth, and population aging, by sex. The blue dashed line (baseline) is the number of deaths from heart disease or cancer that occurred in 1969. The dark yellow (1969--2014) and light yellow (2015--2020) line represents the total number of deaths that would have occurred each year if the population size and age structure remained the same as it was in 1969; this line reflects the effect of changes in population risk. The black (1969--2014) and gray (2015--2020) line represents the total number of deaths that would have occurred if the age structure had remained the same as it was in 1969; this line reflects the effect of changes in risk and population growth. The dark orange (1969--2014) and light orange (2015--2020) line represents the expected number of deaths that actually occurred and thus reflects the combined impact of changes in population risk, growth, and aging. A. Heart disease deaths among men. The number of heart disease deaths attributed to risk declined while the number of heart disease deaths resulting from population growth and aging increased. Observed heart disease deaths declined from 1969 through 2014 and are predicted to increase through 2020, primarily because of an aging population. B. Number of cancer deaths among men. The number of cancer deaths attributed to risk increased from 1969 through 2000 and declined from 2000 forward. The number of cancer deaths resulting from population growth and aging increased. Observed cancer deaths increased from 1969 through 2014 and are predicted to continue to increase through 2020, primarily because of an aging population. C. Number of heart disease deaths among women. The number of heart disease deaths attributed to risk declined while the number of heart disease deaths resulting from population growth and aging increased. Observed heart disease deaths increased from 1969 through 1995, primarily because of an aging population. Observed heart disease deaths are predicted to continue to decrease through 2020, primarily because of continued risk reduction. D. Number of cancer deaths among women. The number of cancer deaths attributed to risk increased from 1969 through 2000 and declined from 2000 forward. The number of cancer deaths resulting from population growth and aging increased. Observed cancer deaths increased from 1969 through 2015 and are predicted to continue to increase through 2020, primarily because of an aging population.](PCD-13-E157s01){#F1}

[Figure 2](#F2){ref-type="fig"} shows the observed (1969--2014) and predicted (2015--2020) number of deaths and death rates for heart disease and cancer by year for all races and both sexes combined. From 2015 to 2020, we predict the number of heart disease deaths overall to stabilize and cancer deaths to increase and surpass heart disease deaths. For 2016, we predict more deaths from cancer than from heart disease (591,426 vs 587,329). In 2020, we predict a total of 627,620 cancer deaths vs 572,415 heart disease deaths.

![Age-standardized death rates (ASDR) and the observed and predicted number of cancer and heart disease deaths from 1969 through 2020 for men and women combined.\
YearCancerHeart DiseaseAge-Standardized Death RateNo. of DeathsAge-Standardized Death Rate forNo. of Deaths**Observed**1969198.6321,764520.4739,0701970198.8329,375502.6735,3631971198.9335,968496.6743,1951972200.4345,961488749,7881973198.7349,563481.7756,9551974199.9358,925457.4738,0581975199.1364,095431.7716,0981976202.3375,658431723,7491977203384,872416.6718,7071978204.4395,099413729,2911979204.5403,388405.2733,0921980207416,497411.1760,9381981206.4422,080398.8753,7381982208.3433,769390.7755,4161983209.2442,957390.6770,3051984210.9453,488380.4765,0021985211.3461,563376.5770,8911986211.8469,365366.7765,1631987211.9476,932357.4760,2461988212.6485,056353.7765,0481989214.3496,180333.0733,7751990214.9505,339320.3719,9541991215.1514,684313.0720,7551992213.5520,586304.4717,6181993213.4529,924308.3743,3801994211.7534,337297.5732,3381995209.9538,487293.3737,4701996207.0539,568285.9733,2801997203.6539,604277.7726,9061998200.8541,569271.3724,8031999200.7549,829266.4725,1452000198.8553,080256.3710,7012001196.3553,760249.0700,0762002194.4557,264244.1696,9002003190.9556,890235.7685,0542004186.8553,880220.9652,4502005185.2559,303216.1652,0542006182.0559,880204.8631,5962007179.3562,867195.2616,0402008176.3565,460191.3616,7992009173.4567,614181.9599,3852010171.7574,738177.2597,6612011168.7576,685173.1596,5502012166.3582,607169.8599,6732013163.0584,872169.1611,0822014161.2591,686166.6614,305**Predicted**2015158.7596,872159.4600,7112016156.2600,951155.5597,5372017153.7606,401151.5594,7072018151.9614,551149.5598,9912019150.2621,914147.4602,1372020148.4629,581145.3606,608](PCD-13-E157s02){#F2}

Discussion
==========

Our projections indicate that cancer will soon become the leading cause of death in the United States if trends in risk of death from cancer and heart disease and population growth and aging continue. In 1969, there were more than twice as many heart disease deaths as cancer deaths. The decline in heart disease rates (risk) began earlier and was steeper than the decline in risk of death from cancer, which occurred approximately 20 years later. The magnitude of heart disease risk reduction has offset the increase in heart disease deaths from population growth and aging, while the decline in risk of cancer deaths only partially offset the increase in cancer deaths resulting from demographic changes related to population growth and aging. These findings are similar among black and white Americans.

Several factors contributed to the decline in heart disease risk. In 1964, the first Surgeon General's report on smoking and health ([@R13]) linked smoking and lung cancer, and a later report linked smoking with the risk of heart attack and stroke, noting that smokers had about twice the risk of dying from heart disease than lifetime nonsmokers ([@R14]). Among smokers, the reduction in excess risk of death from heart disease occurs soon after cessation and is reduced by about half after only one year of smoking abstinence ([@R15]). After 15 years of cessation, the risk of death is slightly elevated, but similar to those who never smoked, supporting the hypothesis that the inflammatory component of cardiovascular disease is reversible. Although the declining risk of dying from heart disease has paralleled the decline in smoking prevalence, treatment of cardiovascular disease risk factors has also improved. Cohorts who were aged 50 to 60 years in the 1970s had a 43% lower 10-year cumulative mortality than similar cohorts who reached that age in the 1950s, with significant reductions in cardiovascular disease risk factors such as lower serum cholesterol levels, lower systolic blood pressure, and better overall blood pressure control ([@R16]). From 1980 to 2000, approximately half of the decline in heart disease death was attributed to improved treatment after acute myocardial infarction or unstable angina, secondary prevention post-myocardial infarction, treatment of heart failure, and revascularization for chronic angina. The remaining decline was attributed to further reductions in the major risk factors --- total cholesterol levels, high blood pressure, and smoking --- and increased physical activity ([@R17]). Further reduction in the risk of heart disease deaths may have been tempered by increases in body mass index and the prevalence of diabetes ([@R18]).

The overall risk of death from heart disease declined in both black and white Americans and, based on our model, is predicted to continue to decline through 2020. Since 1969, the reduction in risk among men has more than offset the increase in heart disease deaths caused by population growth and aging. This reduction in risk has resulted in an overall decline in the observed number of heart disease deaths. However, we predict that the number of heart disease deaths will stabilize or increase slightly in men from 2015 to 2020 as further risk reduction is no longer able to offset the increase in heart disease deaths caused by demographic trends, particularly trends in population aging. A reduction in the number of heart disease deaths among women began more recently and is predicted to continue through 2020.

The overall risk of dying from cancer increased throughout much of the latter part of the last century and is consistent with an increase in the incidence of 4 leading cancers: cancers of the lung and bronchus, colon and rectum, prostate, and female breast ([@R8]). Collectively, these cancers accounted for almost 50% of all cancer deaths in the United States. The cancer death rate began to decline in the early 1990s and was largely driven by a decline in deaths from cancers of the lung and prostate in men, breast cancer in women, and a continued decline in colorectal cancer deaths in both men and women that began in the mid-1980s. Lung cancer death rates in women began to decline in the early 2000s, approximately a decade after the decline began in men.

The decline in lung cancer death rates in both men and women parallels a reduction in tobacco use in each group, offset by a latency period of several decades ([@R19]). Death rates from other tobacco-related cancers have declined as well, likely the result of reduced smoking prevalence as subsequent Surgeon General reports found convincing evidence for a direct causal relationship ([@R20]). Access to quality health care, including early diagnosis through screening, timely follow-up, and evidence-based treatments, is believed to have resulted in increased survival accompanied by reduced mortality from colorectal cancer and, to a lesser extent, female breast cancer and prostate cancer ([@R21]).

The risk of dying from cancer increased among men and women throughout the early 1990s before declining, with further risk reduction predicted through 2020. The increase in the risk of death from cancer from 1969 to the early 1990s exacerbated the increase in cancer deaths caused by demographic changes in population growth and aging, resulting in an overall increase in the observed number of cancer deaths. As the risk of cancer deaths began to decline, the number of deaths continued to increase, although at a slower rate. Underlying these trends in deaths is the predicted number of incident cases of cancer, which is expected to increase by more than 20% from 2010 through 2020, whereas the overall risk of being diagnosed with cancer is predicted to remain stable ([@R22]).

The risk of dying from heart disease and cancer generally increases with age and, as a result, the numbers of heart disease and cancer deaths increase with the growth and aging of the US population. These demographic influences are likely to continue, because the US population is expected to increase by 10% from 2010 to 2020, with the proportion of the population 65 years of age or older increasing from 13% to 16% ([@R5]). The reduction in risk of death from cancer started later than the reduction in risk of death from heart disease and has not been as rapid. Our models estimated that the number of deaths from cancer would surpass the number of deaths from heart disease around 2016, because heart disease deaths were predicted to stabilize or increase slightly in men, and cancer deaths were predicted to continue to increase. Heart disease deaths actually increased in 2013 and again in 2014, somewhat earlier than predicted.

These results are subject to several limitations. This study used methods based on age--period--cohort models that identify trends in younger birth cohorts and extrapolate these trends to future older cohorts ([@R12]). Studies have validated these methods by using long-term cancer incidence data but not heart disease or cancer death data. These predictions are based on trends in risk during the past 10 to 30 years; trends in recent years may differ from long-term trends. As such, predictions of heart disease and cancer deaths may be overestimates, because the risk components in these models do not account for potential recent advances in primary prevention and treatment or national initiatives, such as CDC's Screen for Life: National Colorectal Cancer Action Campaign (<http://www.cdc.gov/cancer/colorectal/sfl/>) or the Million Hearts project (<http://millionhearts.hhs.gov/>). At the same time, our predictions may be underestimates because the risk component may not fully account for the potential effect of increased prevalence of obesity and diabetes on risk for cardiovascular disease or for cancers such as pancreatic cancer, which is increasing and now is the fourth leading cause of cancer-related deaths in the United States ([@R23]).

The population projections used in these predictions are themselves forecasts of the population size and age composition based on assumptions on future births, deaths, and migration. Furthermore, overall life expectancy in the United States is improving even as disparities by race and socioeconomic factors are increasing ([@R24]); these trends are likely to affect population projections. Possible misclassification of underlying cause of death may contribute to imprecision in our estimates.

To counter the anticipated growth in the number of heart disease and cancer deaths, increase the health span of an aging population, and reduce the incidence of heart disease and cancer, a greater emphasis on primary prevention and improved treatment is needed. CDC estimates that each year approximately 91,000 premature deaths from heart disease and 84,000 premature deaths from cancer are potentially preventable ([@R25]). Heart disease and cancer share numerous related risk factors, including tobacco use, obesity, and physical inactivity. Further reductions in deaths might yet be achievable if Healthy People 2020 objectives related to risk factors, early diagnosis, and access to health care are met ([@R26]).
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### CME Questions

1.  You are advising a large public health department about expected mortality rates in coming years. According to the review of mortality data, population estimates, and population projections by Weir and colleagues, which of the following statements about the overall effects of risk reduction and population growth and aging on the projected number of heart disease and cancer deaths to the year 2020 is ***correct***?

    A.  Between 1969 and 2020, the number of heart disease deaths is predicted to decrease by 21.3% among men (−73.9% risk, 17.9% growth, 34.7% aging)

    B.  Between 1969 and 2020, the number of heart disease deaths is predicted to decrease by 7.4% among women

    C.  Between 1969 and 2020, the number of cancer deaths is predicted to increase by 27.1% among men

    D.  Between 1969 and 2020, the number of cancer deaths is predicted to increase by 53.3% among women

2.  According to the review of mortality data, population estimates, and population projections by Weir and colleagues, which of the following statements about factors contributing to the decline in heart disease risk is ***correct***?

    A.  Reducing risk from smoking only occurs after 20 years of cessation

    B.  The inflammatory component of cardiovascular disease is irreversible

    C.  Improved treatment of cardiovascular risk factors has had a marked impact

    D.  From 1980--2000, approximately 20% of decline in heart disease deaths was due to improved treatment of acute myocardial infarction (MI), unstable angina, heart failure, and chronic angina; and secondary prevention after MI

3.  According to the review of mortality data, population estimates, and population projections by Weir and colleagues, which of the following statements about factors associated with the increase in cancer risk is ***correct***?

    A.  Overall risk for cancer deaths increased in parallel with an increase in 4 leading cancers: melanoma, liver, lung, and breast

    B.  Decline in lung cancer death rates in both sexes parallels a reduction in tobacco use, offset by a latency period of several decades

    C.  Cancer death rate began to increase in the early 1990s

    D.  Between 2010 and 2020, the predicted number of incident cases of cancer is expected to remain stable, but the overall risk of being diagnosed with cancer is predicted to increase by more than 20%

###### Evaluation

  ---------------------------------------------------------------------------- ---------------------------- ---------------------------- ---------------------------- --------------------
  **1. The activity supported the learning objectives.**                                                                                                              
  **Strongly Disagree**                                                                                                                                               **Strongly Agree**
  1                                                                            2                            3                            4                            5
  **2. The material was organized clearly for learning to occur.**                                                                                                    
  **Strongly Disagree**                                                                                                                                               **Strongly Agree**
  1                                                                            2                            3                            4                            5
  **3. The content learned from this activity will impact my practice.**                                                                                              
  **Strongly Disagree**                                                        **                      **   **                      **   **                      **   **Strongly Agree**
  1                                                                            2                            3                            4                            5
  **4. The activity was presented objectively and free of commercial bias.**                                                                                          
  **Strongly Disagree**                                                                                                                                               **Strongly Agree**
  1                                                                            2                            3                            4                            5
  ---------------------------------------------------------------------------- ---------------------------- ---------------------------- ---------------------------- --------------------
